Latest News- Anti-Obesity Drugs Market: Class III is expected to lead the Type segment during 2025-2029

The Anti-Obesity Drugs Market is being driven by Growing obese population

The Anti-Obesity Drugs Market is expected to grow at a CAGR of 15.7% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 22905.3 million. The global health crisis of obesity and type 2 diabetes is escalating, with these metabolic disorders contributing to a significant burden of comorbidities, such as hypertension and dyslipidemia, leading to an increased risk of cardiovascular diseases for millions of people worldwide. Body Mass Index (BMI) serves as a robust indicator for both obesity and type 2 diabetes mellitus, with insulin resistance being a common factor linking the two conditions. Several pharmaceutical innovations are under development to address this pressing health concern. Notably, Johnson & Johnson's drug candidate, JNJ-64565111, is currently in phase II trials, positioning it as a potential solution for managing both obesity and type 2 diabetes mellitus. 

Get more information on Anti-Obesity Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Type
  • Class III
  • Class II anti-obesity drugs
  • Class I anti-obesity drugs
• Drug Class
  • Peripherally acting drugs
  • Centrally acting drugs
• Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Drug stores
  • E-commerce
• Route Of Administration
  • Oral route
  • Subcutaneous route
• Geography
  • North America
    • Canada
    • Mexico
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia
    • China
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Growing obese population
• Use of bariatric surgery limited for morbid obesity
• Limited number of approved drugs

However, the market also witnesses some limitations, which are as follows:

• Availability of anti-obesity devices
• Limited reimbursement for anti-obesity drugs
• Low safety and tolerability profile of anti-obesity drugs

Benefits of Buying Global Anti-Obesity Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Anti-Obesity Drugs Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Anti-Obesity Drugs Market focuses on medications that help individuals struggling with weight issues, including those who are obese or overweight. These drugs target various aspects of weight management, such as appetite suppression, boosting metabolism, and hindering fat absorption. Prevalence of obesity and related chronic diseases like insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, arthritis, and lifestyle-related illnesses, fuel the demand for these medicines. Factors contributing to obesity, such as energy imbalance, excessive calorie consumption, stress, smoking, and drinking, are global concerns. Children and adolescents are also affected, leading to a growing endemic.

Market Research Overview

The anti-obesity drugs market is a significant segment of the global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of various obesity treatments. These offerings include non-generic and generic medications, as well as veterinary drugs. According to Technavio, the healthcare market size is determined by the collective revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The expansion of the global pharmaceuticals market will be fueled by several factors, including the increasing global population aging, with the number of individuals aged 60 years and above predicted to rise substantially. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to reach this demographic milestone. This demographic shift will create a substantial demand for obesity treatments, as age-related weight gain is a common issue for older adults. Additionally, factors such as metabolic disorders, unhealthy diets, and sedentary lifestyles contribute to the rising prevalence of obesity, further driving market growth. Pharmaceutical companies are responding to this trend by investing in research and development of novel obesity treatments, focusing on targets such as appetite suppression, metabolism enhancement, and fat absorption inhibition to address the root causes of obesity.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/